Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children

Drilon, A.; Laetsch, T.; Kummar, S.; DuBois, S.; Lassen, U.; Demetri, G.; Nathenson, M.; Doebele, R.; Farago, A.; Pappo, A.; Turpin, B.; Dowlati, A.; Brose, M.; Mascarenhas, L.; Federman, N.; Berlin, J.; El-Deiry, W.; Baik, C.; Deeken, J.; Boni, V.; Nagasubramanian, R.; H. Taylor, Matthew; Rudzinski, E.; Meric-Bernstam, F.; Sohal, D.; Ma, P.; Raez, L.; Hechtman, J.; Benayed, R.; Ladanyi, M.; B. Tuch, Brian; Ebata, K.; Cruickshank, S.; Ku, N.; Cox, M.; Hawkins, D.; Hong, D.; Hyman, D.

doi:10.1056/NEJMoa1714448

Public

Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children

Shared by NobleBlocks on Feb 21, 2018 • 12:00 AM UTC

Authors:

A. Drilon

T. Laetsch

S. Kummar

Abstract

Background Fusions involving one of three tropomyosin receptor kinases (TRK) occur in diverse cancers in children and adults. We evaluated the efficacy and safety of larotrectinib, a highly selective TRK inhibitor, in adults and children who had tumors with these fusions. Methods We enrolled patient...

Subject

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!